Intranasal naloxone

Phase 2Small molecule

NNorwegian University of Science and Technology

Intranasal naloxone is one of 15 small molecule programs targeting Overdose. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OverdoseActive, not recruiting

OverdosePhase 2

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Overdose

#DrugCompanyPhaseTrials

Narcan

SScienture

Approved

2 2

Suboxone

IIndivior Inc.

Approved

—3

Ativan

BBausch Health Americas, Inc.

Phase 2

1 4

Haldol

DDePuy Orthopaedics

Phase 2

1 5

Cysteine Hydrochloride

Novartis

Phase 1

1 6

Acetadote

AArbor Pharmaceuticals, Inc.

Phase 1

1 7

Sublocade

IIndivior Inc.

Phase 3

1 8

Naloxone Intranasal

NNorwegian University of Science and Technology

Phase 3

1 9

Intravenous

IIsfahan University of Medical Sciences

Phase 2

1 10

MS Contin

Merck & Co.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Overdose2 trials

Nasal Naloxone for Narcotic Overdose

Unknown status·JJudith Feinberg·Phase 4·NCT01912573·236 enrolled

Randomized Trial of Intranasal Versus Intravenous Naloxone in Level of Consciousness in Suspected Opioid Overdose

Completed·IIsfahan University of Medical Sciences·Phase 2·NCT01293058·100 enrolled

Tics1 trial

Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use

Completed·NNorwegian University of Science and Technology·Phase 1/2·NCT02307721·12 enrolled

Intravenous1 trial

Pharmacokinetics of Intravenous and Intranasal Formulations of Naloxone in Healthy Volunteers.

Completed·PParc de Salut Mar·Phase 1·NCT06306391·8 enrolled

TED1 trial

Bioavailability of Nasal Naloxone and Injected Naloxone Compared

Completed·NNorwegian University of Science and Technology·Phase 1·NCT02598856·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Intranasal naloxone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intranasal naloxone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intranasal naloxone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Norwegian University of Science and Technology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNorwegian University of Science and Technology

Intranasal naloxone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Overdose2 trials

Tics1 trial

Intravenous1 trial

TED1 trial

References

Drug Info

Quick Facts

Related News